BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fukumoto H, Tennis M, Locascio JJ, Hyman BT, Growdon JH, Irizarry MC. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol. 2003;60:958-964. [PMID: 12873852 DOI: 10.1001/archneur.60.7.958] [Cited by in Crossref: 172] [Cited by in F6Publishing: 191] [Article Influence: 8.6] [Reference Citation Analysis]
Number Citing Articles
1 Natsume S, Baba H, Maeshima H, Saida T, Yoshinari N, Shimizu K, Suzuki T. Clinical course and serum amyloid β levels in elderly patients with major depressive disorder. J Affect Disord 2022;315:156-61. [PMID: 35932935 DOI: 10.1016/j.jad.2022.07.073] [Reference Citation Analysis]
2 Bhuniya S, Goyal M, Chowdhury N, Mishra P. Intermittent hypoxia and sleep disruption in obstructive sleep apnea increase serum tau and amyloid-beta levels. J Sleep Res 2022;:e13566. [PMID: 35165967 DOI: 10.1111/jsr.13566] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Subramanian S, Krishna G, Sivakumar PT, Dahale AB, Kumar J S, Sinha P, Varghese M. Plasma neurofilament L to amyloid β42 ratio in differentiating Alzheimer's type from non-Alzheimer's dementia: A cross-sectional pilot study from India. Asian J Psychiatr 2021;66:102914. [PMID: 34741884 DOI: 10.1016/j.ajp.2021.102914] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
4 Dulla BS, S. B, K. LP. A Study on the Effect of Valeric Acid in Alzheimer's Induced Rats by the Estimation of Aβ 1-42 Biomarker. Journal of Health and Allied Sciences NU. [DOI: 10.1055/s-0041-1736274] [Reference Citation Analysis]
5 Tao D, Xie C, Fu S, Rong S, Song S, Ye H, Jaffrezic-Renault N, Guo Z. Thionine-functionalized three-dimensional carbon nanomaterial-based aptasensor for analysis of Aβ oligomers in serum. Anal Chim Acta 2021;1183:338990. [PMID: 34627525 DOI: 10.1016/j.aca.2021.338990] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
6 Koychev I, Jansen K, Dette A, Shi L, Holling H. Blood-Based ATN Biomarkers of Alzheimer's Disease: A Meta-Analysis. J Alzheimers Dis 2021;79:177-95. [PMID: 33252080 DOI: 10.3233/JAD-200900] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
7 Zecca C, Pasculli G, Tortelli R, Dell'Abate MT, Capozzo R, Barulli MR, Barone R, Accogli M, Arima S, Pollice A, Brescia V, Logroscino G. The Role of Age on Beta-Amyloid1-42 Plasma Levels in Healthy Subjects. Front Aging Neurosci 2021;13:698571. [PMID: 34531734 DOI: 10.3389/fnagi.2021.698571] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
8 Shea TB. Improvement of cognitive performance by a nutraceutical formulation: Underlying mechanisms revealed by laboratory studies. Free Radic Biol Med 2021;174:281-304. [PMID: 34352370 DOI: 10.1016/j.freeradbiomed.2021.07.039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Castillo-Mendieta T, Arana-Lechuga Y, Campos-Peña V, Sosa AL, Orozco-Suarez S, Pinto-Almazán R, Segura-Uribe J, Javier Rodríguez-Sánchez de Tagle A, Ruiz-Sánchez E, Guerra-Araiza C. Plasma Levels of Amyloid-β Peptides and Tau Protein in Mexican Patients with Alzheimer's Disease. J Alzheimers Dis 2021;82:S271-81. [PMID: 34151786 DOI: 10.3233/JAD-200912] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Manafikhi R, Haik MB, Lahdo R, AlQuobaili F. Plasma amyloid β levels in Alzheimer's disease and cognitively normal controls in Syrian population. Med J Islam Repub Iran 2021;35:19. [PMID: 33996670 DOI: 10.47176/mjiri.35.19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Castle M, Fiedler N, Pop LC, Schneider SJ, Schlussel Y, Sukumar D, Hao L, Shapses SA. Three Doses of Vitamin D and Cognitive Outcomes in Older Women: A Double-Blind Randomized Controlled Trial. J Gerontol A Biol Sci Med Sci 2020;75:835-42. [PMID: 30951148 DOI: 10.1093/gerona/glz041] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
12 Miao R, Chen H, Gill S, Naude J, Smith EE, Ismail Z, for the Alzheimer’s Disease Neuroimaging Initiative. Plasma β-amyloid in mild behavioural impairment – neuropsychiatric symptoms on the Alzheimer’s continuum.. [DOI: 10.1101/2021.01.09.21249145] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Deniz K, Ho CCG, Malphrus KG, Reddy JS, Nguyen T, Carnwath TP, Crook JE, Lucas JA, Graff-Radford NR, Carrasquillo MM, Ertekin-Taner N. Plasma Biomarkers of Alzheimer's Disease in African Americans. J Alzheimers Dis 2021;79:323-34. [PMID: 33252078 DOI: 10.3233/JAD-200828] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
14 Herrero-Labrador R, Trueba-Saiz A, Martinez-Rachadell L, Fernandez de Sevilla ME, Zegarra-Valdivia JA, Pignatelli J, Diaz-Pacheco S, Fernandez AM, Torres Aleman I. Circulating Insulin-Like Growth Factor I is Involved in the Effect of High Fat Diet on Peripheral Amyloid β Clearance. Int J Mol Sci 2020;21:E9675. [PMID: 33352990 DOI: 10.3390/ijms21249675] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
15 Wu J, Cao C, Loch RA, Tiiman A, Luo J. Single-molecule studies of amyloid proteins: from biophysical properties to diagnostic perspectives. Q Rev Biophys 2020;53:e12. [PMID: 33148356 DOI: 10.1017/S0033583520000086] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
16 d'Abramo C, D'Adamio L, Giliberto L. Significance of Blood and Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Sensitivity, Specificity and Potential for Clinical Use. J Pers Med 2020;10:E116. [PMID: 32911755 DOI: 10.3390/jpm10030116] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
17 Herrero-labrador R, Trueba-saiz A, Martinez-rachadell L, de Sevilla EF, Diaz-pacheco S, Fernandez AF, Torres Aleman I. DIET INFLUENCES PERIPHERAL AMYLOID β METABOLISM: A ROLE FOR CIRCULATING INSULIN-LIKE GROWTH FACTOR I.. [DOI: 10.1101/2020.07.09.180265] [Reference Citation Analysis]
18 Rehiman SH, Lim SM, Neoh CF, Majeed ABA, Chin AV, Tan MP, Kamaruzzaman SB, Ramasamy K. Proteomics as a reliable approach for discovery of blood-based Alzheimer's disease biomarkers: A systematic review and meta-analysis. Ageing Res Rev 2020;60:101066. [PMID: 32294542 DOI: 10.1016/j.arr.2020.101066] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
19 Lin Y, Chen T, Mao G, Qiu T, Lan Y, Xiang X, Huang J, Huang J, Lu T, Gan S, Sun XD, Zhang J. Long-term and in vivo assessment of Aβ protein-induced brain atrophy in a zebrafish model by optical coherence tomography. J Biophotonics 2020;13:e202000067. [PMID: 32306519 DOI: 10.1002/jbio.202000067] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
20 Li F, Xie X, Sui X, Wang P, Chen Z, Zhang J. Profile of Pathogenic Proteins and MicroRNAs in Plasma-derived Extracellular Vesicles in Alzheimer’s Disease: A Pilot Study. Neuroscience 2020;432:240-6. [DOI: 10.1016/j.neuroscience.2020.02.044] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
21 Zhang S, Huang SY, An XB, Zeng L, Ai J. Medical Histories of Control Subjects Influence the Biomarker Potential of Plasma Aβ in Alzheimer's Disease: a Meta-analysis. J Mol Neurosci 2020;70:861-70. [PMID: 32125624 DOI: 10.1007/s12031-020-01510-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
22 Kim K, Lee CH, Park CB. Chemical sensing platforms for detecting trace-level Alzheimer's core biomarkers. Chem Soc Rev 2020;49:5446-72. [DOI: 10.1039/d0cs00107d] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 9.0] [Reference Citation Analysis]
23 Belrose JC, Noppens RR. Anesthesiology and cognitive impairment: a narrative review of current clinical literature. BMC Anesthesiol 2019;19:241. [PMID: 31881996 DOI: 10.1186/s12871-019-0903-7] [Cited by in Crossref: 55] [Cited by in F6Publishing: 60] [Article Influence: 13.8] [Reference Citation Analysis]
24 Alhajraf F, Ness D, Hye A, Strydom A. Plasma amyloid and tau as dementia biomarkers in Down syndrome: Systematic review and meta-analyses. Dev Neurobiol 2019;79:684-98. [PMID: 31389176 DOI: 10.1002/dneu.22715] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
25 Hampel H, O'Bryant SE, Molinuevo JL, Zetterberg H, Masters CL, Lista S, Kiddle SJ, Batrla R, Blennow K. Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. Nat Rev Neurol 2018;14:639-52. [PMID: 30297701 DOI: 10.1038/s41582-018-0079-7] [Cited by in Crossref: 305] [Cited by in F6Publishing: 312] [Article Influence: 76.3] [Reference Citation Analysis]
26 Talwar P, Gupta R, Kushwaha S, Agarwal R, Saso L, Kukreti S, Kukreti R. Viral Induced Oxidative and Inflammatory Response in Alzheimer's Disease Pathogenesis with Identification of Potential Drug Candidates: A Systematic Review using Systems Biology Approach. Curr Neuropharmacol 2019;17:352-65. [PMID: 29676229 DOI: 10.2174/1570159X16666180419124508] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
27 Guzman-martinez L, Maccioni RB, Farías GA, Fuentes P, Navarrete LP. Biomarkers for Alzheimer’s Disease. CAR 2019;16:518-28. [DOI: 10.2174/1567205016666190517121140] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 8.0] [Reference Citation Analysis]
28 Wolf D, Fischer FU, Fellgiebel A; for the Alzheimer’s Disease Neuroimaging Initiative. Impact of Resilience on the Association Between Amyloid-β and Longitudinal Cognitive Decline in Cognitively Healthy Older Adults. JAD 2019;70:361-70. [DOI: 10.3233/jad-190370] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
29 Fuller SJ, Carrigan N, Sohrabi HR, Martins RN. Current and Developing Methods for Diagnosing Alzheimer's Disease. Neurodegeneration and Alzheimer's Disease 2019. [DOI: 10.1002/9781119356752.ch3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
30 Chiu MJ, Lue LF, Sabbagh MN, Chen TF, Chen HH, Yang SY. Long-Term Storage Effects on Stability of Aβ1-40, Aβ1-42, and Total Tau Proteins in Human Plasma Samples Measured with Immunomagnetic Reduction Assays. Dement Geriatr Cogn Dis Extra 2019;9:77-86. [PMID: 31043966 DOI: 10.1159/000496099] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
31 Ashfaq M, Talreja N, Chuahan D, Srituravanich W. Carbon Nanostructure-Based Materials: A Novel Tool for Detection of Alzheimer’s Disease. Biological, Diagnostic and Therapeutic Advances in Alzheimer's Disease 2019. [DOI: 10.1007/978-981-13-9636-6_4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
32 Yao F, Hong X, Li S, Zhang Y, Zhao Q, Du W, Wang Y, Ni J. Urine-Based Biomarkers for Alzheimer’s Disease Identified Through Coupling Computational and Experimental Methods. JAD 2018;65:421-31. [DOI: 10.3233/jad-180261] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
33 Kumar S, Karthikeyan N, Mishra S, Padmanabhan P, Radda G, Gulyás B. Misfolded Protein Linked Strategies Toward Biomarker Development for Neurodegenerative Diseases. Mol Neurobiol 2019;56:2559-78. [DOI: 10.1007/s12035-018-1232-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
34 Htike TT, Mishra S, Kumar S, Padmanabhan P, Gulyás B. Peripheral Biomarkers for Early Detection of Alzheimer's and Parkinson's Diseases. Mol Neurobiol 2019;56:2256-77. [PMID: 30008073 DOI: 10.1007/s12035-018-1151-4] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
35 Kucheryavykh LY, Kucheryavykh YV, Washington AV, Inyushin MY. Amyloid Beta Peptide Is Released during Thrombosis in the Skin. Int J Mol Sci 2018;19:E1705. [PMID: 29890636 DOI: 10.3390/ijms19061705] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
36 Paraskevaidi M, Martin-Hirsch PL, Martin FL. Progress and Challenges in the Diagnosis of Dementia: A Critical Review. ACS Chem Neurosci 2018;9:446-61. [PMID: 29390184 DOI: 10.1021/acschemneuro.8b00007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
37 Tao Q, Zhu H, Chen X, Stern RA, Kowall N, Au R, Blusztajn JK, Qiu WQ; Alzheimer’s Disease Metabolomics Consortium. Pramlintide: The Effects of a Single Drug Injection on Blood Phosphatidylcholine Profile for Alzheimer's Disease. J Alzheimers Dis 2018;62:597-609. [PMID: 29480193 DOI: 10.3233/JAD-170948] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
38 Wang D, Di X, Fu L, Li Y, Han X, Wu H, Cai L, Meng X, Jiang C, Kong W, Su W. Analysis of serum β-amyloid peptides, α2-macroglobulin, complement factor H, and clusterin levels in APP/PS1 transgenic mice during progression of Alzheimer's disease. Neuroreport 2016;27:1114-9. [PMID: 27541273 DOI: 10.1097/WNR.0000000000000661] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
39 Ishijima S, Baba H, Maeshima H, Shimano T, Inoue M, Suzuki T, Arai H. Glucocorticoid may influence amyloid β metabolism in patients with depression. Psychiatry Research 2018;259:191-6. [DOI: 10.1016/j.psychres.2017.10.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
40 Tsou H, Hsu W, Fuh J, Chen S, Liu T, Wang H. Alterations in Acrolein Metabolism Contribute to Alzheimer’s Disease. JAD 2017;61:571-80. [DOI: 10.3233/jad-170736] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
41 Hsu JL, Lee WJ, Liao YC, Wang SJ, Fuh JL. The clinical significance of plasma clusterin and Aβ in the longitudinal follow-up of patients with Alzheimer's disease. Alzheimers Res Ther 2017;9:91. [PMID: 29169407 DOI: 10.1186/s13195-017-0319-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
42 Karelina T, Demin O Jr, Demin O, Duvvuri S, Nicholas T. Studying the Progression of Amyloid Pathology and Its Therapy Using Translational Longitudinal Model of Accumulation and Distribution of Amyloid Beta. CPT Pharmacometrics Syst Pharmacol 2017;6:676-85. [PMID: 28913897 DOI: 10.1002/psp4.12249] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
43 Karelina T, Demin O, Nicholas T, Lu Y, Duvvuri S, Barton HA. A Translational Systems Pharmacology Model for Aβ Kinetics in Mouse, Monkey, and Human. CPT Pharmacometrics Syst Pharmacol 2017;6:666-75. [PMID: 28571112 DOI: 10.1002/psp4.12211] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
44 Yang SY, Chiu MJ, Chen TF, Horng HE. Detection of Plasma Biomarkers Using Immunomagnetic Reduction: A Promising Method for the Early Diagnosis of Alzheimer's Disease. Neurol Ther 2017;6:37-56. [PMID: 28733955 DOI: 10.1007/s40120-017-0075-7] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 7.3] [Reference Citation Analysis]
45 Ovod V, Ramsey KN, Mawuenyega KG, Bollinger JG, Hicks T, Schneider T, Sullivan M, Paumier K, Holtzman DM, Morris JC, Benzinger T, Fagan AM, Patterson BW, Bateman RJ. Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement 2017;13:841-9. [PMID: 28734653 DOI: 10.1016/j.jalz.2017.06.2266] [Cited by in Crossref: 291] [Cited by in F6Publishing: 309] [Article Influence: 48.5] [Reference Citation Analysis]
46 Hsu JL, Lee WJ, Liao YC, Lirng JF, Wang SJ, Fuh JL. Plasma biomarkers are associated with agitation and regional brain atrophy in Alzheimer's disease. Sci Rep 2017;7:5035. [PMID: 28698646 DOI: 10.1038/s41598-017-05390-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
47 El Shebini SM, Abdel-moat M, Kazem YI, Ahmed NH, Fouad S, Mohamed MS, Hussein AMS, Hanna LM, Tapozada ST. Relation Between Obesity, Cognition and Serum Amyloid β Protein Level and Potential Role of Foeniculum vulgare in Reducing Weight and Improving Cognitive Functions. J of Biological Sciences 2017;17:202-212. [DOI: 10.3923/jbs.2017.202.212] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
48 Park JC, Han SH, Cho HJ, Byun MS, Yi D, Choe YM, Kang S, Jung ES, Won SJ, Kim EH, Kim YK, Lee DY, Mook-Jung I. Chemically treated plasma Aβ is a potential blood-based biomarker for screening cerebral amyloid deposition. Alzheimers Res Ther 2017;9:20. [PMID: 28330509 DOI: 10.1186/s13195-017-0248-8] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 6.8] [Reference Citation Analysis]
49 Zhu H, Stern RA, Tao Q, Bourlas A, Essis MD, Chivukula M, Rosenzweig J, Steenkamp D, Xia W, Mercier GA, Tripodis Y, Farlow M, Kowall N, Qiu WQ. An amylin analog used as a challenge test for Alzheimer's disease. Alzheimers Dement (N Y) 2017;3:33-43. [PMID: 28503657 DOI: 10.1016/j.trci.2016.12.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
50 Wallin C, Luo J, Jarvet J, Wärmländer SKTS, Gräslund A. The Amyloid-β Peptide in Amyloid Formation Processes: Interactions with Blood Proteins and Naturally Occurring Metal Ions. Isr J Chem 2017;57:674-85. [DOI: 10.1002/ijch.201600105] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
51 Song L, Lachno DR, Hanlon D, Shepro A, Jeromin A, Gemani D, Talbot JA, Racke MM, Dage JL, Dean RA. A digital enzyme-linked immunosorbent assay for ultrasensitive measurement of amyloid-β 1-42 peptide in human plasma with utility for studies of Alzheimer's disease therapeutics. Alzheimers Res Ther 2016;8:58. [PMID: 27978855 DOI: 10.1186/s13195-016-0225-7] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 6.7] [Reference Citation Analysis]
52 Kleinschmidt M, Schoenfeld R, Göttlich C, Bittner D, Metzner JE, Leplow B, Demuth HU. Characterizing Aging, Mild Cognitive Impairment, and Dementia with Blood-Based Biomarkers and Neuropsychology. J Alzheimers Dis 2016;50:111-26. [PMID: 26639953 DOI: 10.3233/JAD-143189] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
53 Hu Y, Shi S, Liu X, Hu Z, Huang W, Wang D, Xu J, Cheng B, Fang X, Shu Q. Effects of Heart Bypass Surgery on Plasma Aβ40 and Aβ42 Levels in Infants and Young Children. Medicine (Baltimore) 2016;95:e2684. [PMID: 26871797 DOI: 10.1097/MD.0000000000002684] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
54 Conti E, Tremolizzo L, Santarone ME, Tironi M, Radice I, Zoia CP, Aliprandi A, Salmaggi A, Dominici R, Casati M, Appollonio I, Ferrarese C. Donepezil modulates the endogenous immune response: implications for Alzheimer's disease. Hum Psychopharmacol 2016;31:296-303. [PMID: 27297668 DOI: 10.1002/hup.2538] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
55 Inoue M, Baba H, Yamamoto K, Shimada H, Yamakawa Y, Suzuki T, Miki T, Arai H. Serum Levels of Albumin-β-Amyloid Complex in Patients with Depression. Am J Geriatr Psychiatry 2016;24:764-72. [PMID: 27401050 DOI: 10.1016/j.jagp.2016.05.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
56 Khan T. Peripheral Fluid-Based Biomarkers of Alzheimer’s Disease. Biomarkers in Alzheimer's Disease 2016. [DOI: 10.1016/b978-0-12-804832-0.00006-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
57 Igarashi K, Yoshida M, Waragai M, Kashiwagi K. Evaluation of dementia by acrolein, amyloid-β and creatinine. Clinica Chimica Acta 2015;450:56-63. [DOI: 10.1016/j.cca.2015.07.017] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 3.5] [Reference Citation Analysis]
58 Ritter A, Cummings J. Fluid Biomarkers in Clinical Trials of Alzheimer's Disease Therapeutics. Front Neurol 2015;6:186. [PMID: 26379620 DOI: 10.3389/fneur.2015.00186] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
59 Shanthi KB, Krishnan S, Rani P. A systematic review and meta-analysis of plasma amyloid 1-42 and tau as biomarkers for Alzheimer's disease. SAGE Open Med 2015;3:2050312115598250. [PMID: 26770797 DOI: 10.1177/2050312115598250] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
60 Wu G, Wu Z, Na S, Hershey JC. Quantitative assessment of Aβ peptide in brain, cerebrospinal fluid and plasma following oral administration of γ-secretase inhibitor MRK-560 in rats. International Journal of Neuroscience 2014;125:616-24. [DOI: 10.3109/00207454.2014.952730] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
61 Yoshida M, Higashi K, Kuni K, Mizoi M, Saiki R, Nakamura M, Waragai M, Uemura K, Toida T, Kashiwagi K, Igarashi K. Distinguishing mild cognitive impairment from Alzheimer's disease with acrolein metabolites and creatinine in urine. Clin Chim Acta 2015;441:115-21. [PMID: 25542982 DOI: 10.1016/j.cca.2014.12.023] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
62 Benedict C, Byberg L, Cedernaes J, Hogenkamp PS, Giedratis V, Kilander L, Lind L, Lannfelt L, Schiöth HB. Self-reported sleep disturbance is associated with Alzheimer's disease risk in men. Alzheimers Dement 2015;11:1090-7. [PMID: 25438949 DOI: 10.1016/j.jalz.2014.08.104] [Cited by in Crossref: 95] [Cited by in F6Publishing: 100] [Article Influence: 10.6] [Reference Citation Analysis]
63 Cho SM, Kim HV, Lee S, Kim HY, Kim W, Kim TS, Kim DJ, Kim Y. Correlations of amyloid-β concentrations between CSF and plasma in acute Alzheimer mouse model. Sci Rep 2014;4:6777. [PMID: 25345439 DOI: 10.1038/srep06777] [Cited by in Crossref: 23] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]
64 Donohue MC, Moghadam SH, Roe AD, Sun CK, Edland SD, Thomas RG, Petersen RC, Sano M, Galasko D, Aisen PS, Rissman RA. Longitudinal plasma amyloid beta in Alzheimer's disease clinical trials. Alzheimers Dement 2015;11:1069-79. [PMID: 25301682 DOI: 10.1016/j.jalz.2014.07.156] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
65 Huang Y, Potter R, Sigurdson W, Kasten T, Connors R, Morris JC, Benzinger T, Mintun M, Ashwood T, Ferm M, Budd SL, Bateman RJ. β-amyloid dynamics in human plasma. Arch Neurol 2012;69:1591-7. [PMID: 23229043 DOI: 10.1001/archneurol.2012.18107] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 5.3] [Reference Citation Analysis]
66 Fiandaca MS, Kapogiannis D, Mapstone M, Boxer A, Eitan E, Schwartz JB, Abner EL, Petersen RC, Federoff HJ, Miller BL, Goetzl EJ. Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: A case-control study. Alzheimers Dement. 2015;11:600-7.e1. [PMID: 25130657 DOI: 10.1016/j.jalz.2014.06.008] [Cited by in Crossref: 485] [Cited by in F6Publishing: 445] [Article Influence: 53.9] [Reference Citation Analysis]
67 Mocali A, Della Malva N, Abete C, Mitidieri Costanza VA, Bavazzano A, Boddi V, Sanchez L, Dessì S, Pani A, Paoletti F. Altered proteolysis in fibroblasts of Alzheimer patients with predictive implications for subjects at risk of disease. Int J Alzheimers Dis 2014;2014:520152. [PMID: 24949214 DOI: 10.1155/2014/520152] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
68 Sanchez-Espinosa MP, Atienza M, Cantero JL. Sleep deficits in mild cognitive impairment are related to increased levels of plasma amyloid-β and cortical thinning. Neuroimage 2014;98:395-404. [PMID: 24845621 DOI: 10.1016/j.neuroimage.2014.05.027] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 4.0] [Reference Citation Analysis]
69 Gonzalez-Escamilla G, Atienza M, Cantero JL. Impaired cortical oscillatory coupling in mild cognitive impairment: anatomical substrate and ApoE4 effects. Brain Struct Funct 2015;220:1721-37. [PMID: 24682246 DOI: 10.1007/s00429-014-0757-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
70 Weinstein G, Seshadri S. Circulating biomarkers that predict incident dementia. Alzheimers Res Ther 2014;6:6. [PMID: 25031629 DOI: 10.1186/alzrt235] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
71 Reitz C, Mayeux R. Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol 2014;88:640-51. [PMID: 24398425 DOI: 10.1016/j.bcp.2013.12.024] [Cited by in Crossref: 693] [Cited by in F6Publishing: 731] [Article Influence: 77.0] [Reference Citation Analysis]
72 Martí-Fàbregas J, Delgado-Mederos R, Marín R, de la Ossa NP, Alonso de Leciñana M, Rodríguez-Yáñez M, Sanahuja J, Purroy F, De Arce AM, Carrera D, Dinia L, Guardia-Laguarta C, Lleó A. Prognostic value of plasma β-amyloid levels in patients with acute intracerebral hemorrhage. Stroke 2014;45:413-7. [PMID: 24385273 DOI: 10.1161/STROKEAHA.113.002838] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
73 Wang T, Xiao S, Liu Y, Lin Z, Su N, Li X, Li G, Zhang M, Fang Y. The efficacy of plasma biomarkers in early diagnosis of Alzheimer's disease. Int J Geriatr Psychiatry 2014;29:713-9. [PMID: 24318929 DOI: 10.1002/gps.4053] [Cited by in Crossref: 34] [Cited by in F6Publishing: 40] [Article Influence: 3.4] [Reference Citation Analysis]
74 Ruiz A, Pesini P, Espinosa A, Pérez-Grijalba V, Valero S, Sotolongo-Grau O, Alegret M, Monleón I, Lafuente A, Buendía M, Ibarria M, Ruiz S, Hernández I, San José I, Tárraga L, Boada M, Sarasa M. Blood amyloid beta levels in healthy, mild cognitive impairment and Alzheimer's disease individuals: replication of diastolic blood pressure correlations and analysis of critical covariates. PLoS One 2013;8:e81334. [PMID: 24312290 DOI: 10.1371/journal.pone.0081334] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.1] [Reference Citation Analysis]
75 Rembach A, Ryan TM, Roberts BR, Doecke JD, Wilson WJ, Watt AD, Barnham KJ, Masters CL. Progress towards a consensus on biomarkers for Alzheimer’s disease: a review of peripheral analytes. Biomarkers in Medicine 2013;7:641-62. [DOI: 10.2217/bmm.13.59] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
76 Maftei M, Thurm F, Schnack C, Tumani H, Otto M, Elbert T, Kolassa IT, Przybylski M, Manea M, von Arnim CA. Increased levels of antigen-bound β-amyloid autoantibodies in serum and cerebrospinal fluid of Alzheimer's disease patients. PLoS One 2013;8:e68996. [PMID: 23874844 DOI: 10.1371/journal.pone.0068996] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 3.4] [Reference Citation Analysis]
77 Gupta VB, Sundaram R, Martins RN. Multiplex biomarkers in blood. Alzheimers Res Ther 2013;5:31. [PMID: 23795953 DOI: 10.1186/alzrt185] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
78 Gabelle A, Richard F, Gutierrez LA, Schraen S, Delva F, Rouaud O, Buée L, Dartigues JF, Touchon J, Lambert JC, Berr C. Plasma amyloid-β levels and prognosis in incident dementia cases of the 3-City Study. J Alzheimers Dis 2013;33:381-91. [PMID: 22976074 DOI: 10.3233/JAD-2012-121147] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
79 Yang H, Sheen Y, Kao C, Chang C, Hu Y, Lin J. Association between the characteristics of metabolic syndrome and Alzheimer’s disease. Metab Brain Dis 2013;28:597-604. [DOI: 10.1007/s11011-013-9406-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
80 Tan WW, Heckman MG, Vishnu P, Crook JE, Younkin LH, Covil EG, Ferman TJ, Graff-Radford NR, Younkin SG, Smallridge RC, Wehle MJ, Buskirk SJ. Effect of leuprolide on serum amyloid-β peptide levels and memory in patients with prostate cancer with biochemical recurrence. Urology 2013;81:150-4. [PMID: 23273081 DOI: 10.1016/j.urology.2012.08.066] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
81 Rembach A, Faux NG, Watt AD, Pertile KK, Rumble RL, Trounson BO, Fowler CJ, Roberts BR, Perez KA, Li QX, Laws SM, Taddei K, Rainey-Smith S, Robertson JS, Vandijck M, Vanderstichele H, Barnham KJ, Ellis KA, Szoeke C, Macaulay L, Rowe CC, Villemagne VL, Ames D, Martins RN, Bush AI, Masters CL; AIBL research group. Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease. Alzheimers Dement 2014;10:53-61. [PMID: 23491263 DOI: 10.1016/j.jalz.2012.12.006] [Cited by in Crossref: 88] [Cited by in F6Publishing: 81] [Article Influence: 8.8] [Reference Citation Analysis]
82 Toledo JB, Shaw LM, Trojanowski JQ. Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker. Alzheimers Res Ther 2013;5:8. [PMID: 23470128 DOI: 10.1186/alzrt162] [Cited by in Crossref: 95] [Cited by in F6Publishing: 103] [Article Influence: 9.5] [Reference Citation Analysis]
83 Pérez-Torres CJ, Reynolds JO, Pautler RG. Use of magnetization transfer contrast MRI to detect early molecular pathology in Alzheimer's disease. Magn Reson Med 2014;71:333-8. [PMID: 23413044 DOI: 10.1002/mrm.24665] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
84 Bazenet C, Lovestone S. Plasma biomarkers for Alzheimer's disease: much needed but tough to find. Biomark Med 2012;6:441-54. [PMID: 22917146 DOI: 10.2217/bmm.12.48] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 3.3] [Reference Citation Analysis]
85 Zhang Y, Zhou B, Deng B, Zhang F, Wu J, Wang Y, Le Y, Zhai Q. Amyloid-β induces hepatic insulin resistance in vivo via JAK2. Diabetes 2013;62:1159-66. [PMID: 23223021 DOI: 10.2337/db12-0670] [Cited by in Crossref: 62] [Cited by in F6Publishing: 66] [Article Influence: 5.6] [Reference Citation Analysis]
86 Kiko T, Nakagawa K, Satoh A, Tsuduki T, Furukawa K, Arai H, Miyazawa T. Amyloid β levels in human red blood cells. PLoS One 2012;7:e49620. [PMID: 23166730 DOI: 10.1371/journal.pone.0049620] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 5.0] [Reference Citation Analysis]
87 Zhu H, Bhadelia RA, Liu Z, Vu L, Li H, Scott T, Bergethon P, Mwamburi M, Rosenzweig JL, Rosenberg I, Qiu WQ. The association between small vessel infarcts and the activities of amyloid-β peptide degrading proteases in apolipoprotein E4 allele carriers. Angiology 2013;64:614-20. [PMID: 23076436 DOI: 10.1177/0003319712462125] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
88 Shimizu T, Yoshimune K, Komoriya T, Akiyama T, Ye X, Kohno H. Monoclonal antibodies against large oval aggregates of Aβ1-42. J Biosci Bioeng 2013;115:216-20. [PMID: 23041139 DOI: 10.1016/j.jbiosc.2012.09.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
89 Piccinni A, Origlia N, Veltri A, Vizzaccaro C, Marazziti D, Vanelli F, Moroni I, Domenici L, Dell'osso L. Neurodegeneration, β-amyloid and mood disorders: state of the art and future perspectives: β-Amyloid in mood disorders. Int J Geriatr Psychiatry 2013;28:661-71. [DOI: 10.1002/gps.3879] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
90 Takeda S, Sato N, Uchio-Yamada K, Yu H, Moriguchi A, Rakugi H, Morishita R. Oral glucose loading modulates plasma β-amyloid level in alzheimer's disease patients: potential diagnostic method for Alzheimer's disease. Dement Geriatr Cogn Disord 2012;34:25-30. [PMID: 22889768 DOI: 10.1159/000338704] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
91 Chintamaneni M, Bhaskar M. Biomarkers in Alzheimer's disease: a review. ISRN Pharmacol 2012;2012:984786. [PMID: 22811931 DOI: 10.5402/2012/984786] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
92 Zhou L, Chan KH, Chu LW, Kwan JS, Song YQ, Chen LH, Ho PW, Cheng OY, Ho JW, Lam KS. Plasma amyloid-β oligomers level is a biomarker for Alzheimer's disease diagnosis. Biochem Biophys Res Commun 2012;423:697-702. [PMID: 22704931 DOI: 10.1016/j.bbrc.2012.06.017] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 4.0] [Reference Citation Analysis]
93 Mukaetova-Ladinska EB, Abdel-All Z, Dodds S, Andrade J, Alves da Silva J, Kalaria RN, O'Brien JT. Platelet immunoglobulin and amyloid precursor protein as potential peripheral biomarkers for Alzheimer's disease: findings from a pilot study. Age Ageing 2012;41:408-12. [PMID: 22258116 DOI: 10.1093/ageing/afr171] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
94 Zhang Y, Zhou B, Zhang F, Wu J, Hu Y, Liu Y, Zhai Q. Amyloid-β induces hepatic insulin resistance by activating JAK2/STAT3/SOCS-1 signaling pathway. Diabetes 2012;61:1434-43. [PMID: 22522613 DOI: 10.2337/db11-0499] [Cited by in Crossref: 76] [Cited by in F6Publishing: 77] [Article Influence: 6.9] [Reference Citation Analysis]
95 Mayeux R, Schupf N. Blood-based biomarkers for Alzheimer's disease: plasma Aβ40 and Aβ42, and genetic variants. Neurobiol Aging 2011;32 Suppl 1:S10-9. [PMID: 22078169 DOI: 10.1016/j.neurobiolaging.2011.09.004] [Cited by in Crossref: 54] [Cited by in F6Publishing: 57] [Article Influence: 4.9] [Reference Citation Analysis]
96 Rissman RA, Trojanowski JQ, Shaw LM, Aisen PS. Longitudinal plasma amyloid beta as a biomarker of Alzheimer's disease. J Neural Transm (Vienna) 2012;119:843-50. [PMID: 22354745 DOI: 10.1007/s00702-012-0772-4] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 4.1] [Reference Citation Analysis]
97 Mazumdar M, Xia W, Hofmann O, Gregas M, Ho Sui S, Hide W, Yang T, Needleman HL, Bellinger DC. Prenatal lead levels, plasma amyloid β levels, and gene expression in young adulthood. Environ Health Perspect 2012;120:702-7. [PMID: 22313790 DOI: 10.1289/ehp.1104474] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 4.1] [Reference Citation Analysis]
98 Song F, Poljak A, Valenzuela M, Mayeux R, Smythe GA, Sachdev PS. Meta-analysis of plasma amyloid-β levels in Alzheimer's disease. J Alzheimers Dis 2011;26:365-75. [PMID: 21709378 DOI: 10.3233/JAD-2011-101977] [Cited by in Crossref: 87] [Cited by in F6Publishing: 97] [Article Influence: 7.9] [Reference Citation Analysis]
99 Head E, Doran E, Nistor M, Hill M, Schmitt FA, Haier RJ, Lott IT. Plasma amyloid-β as a function of age, level of intellectual disability, and presence of dementia in Down syndrome. J Alzheimers Dis 2011;23:399-409. [PMID: 21116050 DOI: 10.3233/JAD-2010-101335] [Cited by in Crossref: 48] [Cited by in F6Publishing: 56] [Article Influence: 4.0] [Reference Citation Analysis]
100 Toledo JB, Vanderstichele H, Figurski M, Aisen PS, Petersen RC, Weiner MW, Jack CR Jr, Jagust W, Decarli C, Toga AW, Toledo E, Xie SX, Lee VM, Trojanowski JQ, Shaw LM; Alzheimer’s Disease Neuroimaging Initiative. Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol 2011;122:401-13. [PMID: 21805181 DOI: 10.1007/s00401-011-0861-8] [Cited by in Crossref: 123] [Cited by in F6Publishing: 132] [Article Influence: 10.3] [Reference Citation Analysis]
101 Noelker C, Hampel H, Dodel R. Blood-based protein biomarkers for diagnosis and classification of neurodegenerative diseases: current progress and clinical potential. Mol Diagn Ther 2011;15:83-102. [PMID: 21623645 DOI: 10.1007/BF03256398] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
102 Shim YS, Morris JC. Biomarkers predicting Alzheimer's disease in cognitively normal aging. J Clin Neurol 2011;7:60-8. [PMID: 21779293 DOI: 10.3988/jcn.2011.7.2.60] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
103 Fan J, Stukas S, Wong C, Chan J, May S, DeValle N, Hirsch-Reinshagen V, Wilkinson A, Oda MN, Wellington CL. An ABCA1-independent pathway for recycling a poorly lipidated 8.1 nm apolipoprotein E particle from glia. J Lipid Res 2011;52:1605-16. [PMID: 21705806 DOI: 10.1194/jlr.M014365] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
104 Namjoshi D, Stukas S, Wellington CL. ABCA1, apoE and apoA-I as potential therapeutic targets for treating Alzheimer’s disease. Neurodegenerative Disease Management 2011;1:245-259. [DOI: 10.2217/nmt.11.23] [Reference Citation Analysis]
105 Cummings JL. Biomarkers in Alzheimer's disease drug development. Alzheimers Dement 2011;7:e13-44. [PMID: 21550318 DOI: 10.1016/j.jalz.2010.06.004] [Cited by in Crossref: 75] [Cited by in F6Publishing: 82] [Article Influence: 6.3] [Reference Citation Analysis]
106 Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. Nat Rev Neurol. 2011;7:137-152. [PMID: 21304480 DOI: 10.1038/nrneurol.2011.2] [Cited by in Crossref: 961] [Cited by in F6Publishing: 1025] [Article Influence: 80.1] [Reference Citation Analysis]
107 Yaffe K, Weston A, Graff-Radford NR, Satterfield S, Simonsick EM, Younkin SG, Younkin LH, Kuller L, Ayonayon HN, Ding J, Harris TB. Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA 2011;305:261-6. [PMID: 21245181 DOI: 10.1001/jama.2010.1995] [Cited by in Crossref: 155] [Cited by in F6Publishing: 170] [Article Influence: 12.9] [Reference Citation Analysis]
108 Špeljko T, Jutric D, Šimić G. HSV1 in Alzheimer’s disease: Myth or reality? Translational Neuroscience 2011;2. [DOI: 10.2478/s13380-011-0009-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
109 Schupf N, Zigman WB, Tang MX, Pang D, Mayeux R, Mehta P, Silverman W. Change in plasma Aß peptides and onset of dementia in adults with Down syndrome. Neurology 2010;75:1639-44. [PMID: 21041786 DOI: 10.1212/WNL.0b013e3181fb448b] [Cited by in Crossref: 61] [Cited by in F6Publishing: 63] [Article Influence: 4.7] [Reference Citation Analysis]
110 Valeo T. Biomarker Identified for Accelerated Aging in Down Syndrome. Neurology Today 2010;10:1. [DOI: 10.1097/01.nt.0000390835.96723.4a] [Reference Citation Analysis]
111 Matsuoka Y, Andrews HF, Becker AG, Gray AJ, Mehta PD, Sano MC, Dalton AJ, Aisen PS. The relationship of plasma Abeta levels to dementia in aging individuals with Down syndrome. Alzheimer Dis Assoc Disord 2009;23:315-8. [PMID: 19571732 DOI: 10.1097/WAD.0b013e3181aba61e] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
112 Anoop A, Singh PK, Jacob RS, Maji SK. CSF Biomarkers for Alzheimer's Disease Diagnosis. Int J Alzheimers Dis 2010;2010:606802. [PMID: 20721349 DOI: 10.4061/2010/606802] [Cited by in Crossref: 55] [Cited by in F6Publishing: 69] [Article Influence: 4.2] [Reference Citation Analysis]
113 Takeda S, Sato N, Rakugi H, Morishita R. Plasma beta-amyloid as potential biomarker of Alzheimer disease: possibility of diagnostic tool for Alzheimer disease. Mol Biosyst 2010;6:1760-6. [PMID: 20567751 DOI: 10.1039/c003148h] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 1.5] [Reference Citation Analysis]
114 Zheng Y, He J, Hong T. Biomarkers of Alzheimer's disease in body fluids. Sci China Life Sci 2010;53:490-6. [PMID: 20596916 DOI: 10.1007/s11427-010-0081-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
115 Thambisetty M, Lovestone S. Blood-based biomarkers of Alzheimer's disease: challenging but feasible. Biomark Med 2010;4:65-79. [PMID: 20387303 DOI: 10.2217/bmm.09.84] [Cited by in Crossref: 126] [Cited by in F6Publishing: 131] [Article Influence: 9.7] [Reference Citation Analysis]
116 Fukumoto H, Tokuda T, Kasai T, Ishigami N, Hidaka H, Kondo M, Allsop D, Nakagawa M. High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. FASEB J. 2010;24:2716-2726. [PMID: 20339023 DOI: 10.1096/fj.09-150359] [Cited by in Crossref: 176] [Cited by in F6Publishing: 192] [Article Influence: 13.5] [Reference Citation Analysis]
117 Fagan AM, Mintun MA, Shah AR, Aldea P, Roe CM, Mach RH, Marcus D, Morris JC, Holtzman DM. Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med 2009;1:371-80. [PMID: 20049742 DOI: 10.1002/emmm.200900048] [Cited by in Crossref: 227] [Cited by in F6Publishing: 259] [Article Influence: 17.5] [Reference Citation Analysis]
118 Sun X, Chiu CC, Liebson E, Crivello NA, Wang L, Claunch J, Folstein M, Rosenberg I, Mwamburi DM, Peter I, Qiu WQ. Depression and plasma amyloid beta peptides in the elderly with and without the apolipoprotein E4 allele. Alzheimer Dis Assoc Disord 2009;23:238-44. [PMID: 19812466 DOI: 10.1097/WAD.0b013e31819cb3ac] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 2.5] [Reference Citation Analysis]
119 Cummings JL. Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials. Alzheimers Dement. 2006;2:263-271. [PMID: 19595897 DOI: 10.1016/j.jalz.2006.07.001] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 2.4] [Reference Citation Analysis]
120 Rózga M, Bal W. The Cu(II)/Aβ/Human Serum Albumin Model of Control Mechanism for Copper-Related Amyloid Neurotoxicity. Chem Res Toxicol 2010;23:298-308. [DOI: 10.1021/tx900358j] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 3.0] [Reference Citation Analysis]
121 Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T. Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging 2011;32:1626-33. [PMID: 19923038 DOI: 10.1016/j.neurobiolaging.2009.10.009] [Cited by in Crossref: 258] [Cited by in F6Publishing: 286] [Article Influence: 18.4] [Reference Citation Analysis]
122 Okereke OI, Xia W, Selkoe DJ, Grodstein F. Ten-year change in plasma amyloid beta levels and late-life cognitive decline. Arch Neurol 2009;66:1247-53. [PMID: 19822780 DOI: 10.1001/archneurol.2009.207] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 2.6] [Reference Citation Analysis]
123 Schneider P, Hampel H, Buerger K. Biological marker candidates of Alzheimer's disease in blood, plasma, and serum. CNS Neurosci Ther. 2009;15:358-374. [PMID: 19840034 DOI: 10.1111/j.1755-5949.2009.00104.x] [Cited by in Crossref: 101] [Cited by in F6Publishing: 108] [Article Influence: 7.2] [Reference Citation Analysis]
124 Gomis M, Sobrino T, Ois A, Millán M, Rodríguez-campello A, de la Ossa NP, Rodríguez-gonzález R, Jiménez-conde J, Cuadrado-godia E, Roquer J, Dávalos A. Plasma β-Amyloid 1-40 Is Associated With the Diffuse Small Vessel Disease Subtype. Stroke 2009;40:3197-201. [DOI: 10.1161/strokeaha.109.559641] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 2.6] [Reference Citation Analysis]
125 Marcello A, Wirths O, Schneider-Axmann T, Degerman-Gunnarsson M, Lannfelt L, Bayer TA. Reduced levels of IgM autoantibodies against N-truncated pyroglutamate Aβ in plasma of patients with Alzheimer's disease. Neurobiol Aging 2011;32:1379-87. [PMID: 19781815 DOI: 10.1016/j.neurobiolaging.2009.08.011] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
126 Le Bastard N, Aerts L, Leurs J, Blomme W, De Deyn PP, Engelborghs S. No correlation between time-linked plasma and CSF Abeta levels. Neurochem Int 2009;55:820-5. [PMID: 19695299 DOI: 10.1016/j.neuint.2009.08.006] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 2.8] [Reference Citation Analysis]
127 Okereke OI, Xia W, Irizarry MC, Sun X, Qiu WQ, Fagan AM, Mehta PD, Hyman BT, Selkoe DJ, Grodstein F. Performance characteristics of plasma amyloid-beta 40 and 42 assays. J Alzheimers Dis 2009;16:277-85. [PMID: 19221417 DOI: 10.3233/JAD-2009-0948] [Cited by in Crossref: 19] [Cited by in F6Publishing: 25] [Article Influence: 1.4] [Reference Citation Analysis]
128 Song F, Poljak A, Smythe GA, Sachdev P. Plasma biomarkers for mild cognitive impairment and Alzheimer's disease. Brain Res Rev. 2009;61:69-80. [PMID: 19464319 DOI: 10.1016/j.brainresrev.2009.05.003] [Cited by in Crossref: 117] [Cited by in F6Publishing: 127] [Article Influence: 8.4] [Reference Citation Analysis]
129 Takeda S, Sato N, Uchio-Yamada K, Sawada K, Kunieda T, Takeuchi D, Kurinami H, Shinohara M, Rakugi H, Morishita R. Elevation of plasma beta-amyloid level by glucose loading in Alzheimer mouse models. Biochem Biophys Res Commun 2009;385:193-7. [PMID: 19450564 DOI: 10.1016/j.bbrc.2009.05.037] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
130 Wied CCG, Kritsidima M, Elferink AJA. The validity of biomarkers as surrogate endpoints in Alzheimer’s disease by means of the Quantitative Surrogate Validation Level of Evidence Scheme (QSVLES). J Nutr Health Aging 2009;13:376-87. [DOI: 10.1007/s12603-009-0049-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
131 Marcello A, Wirths O, Schneider-Axmann T, Degerman-Gunnarsson M, Lannfelt L, Bayer TA. Circulating immune complexes of Abeta and IgM in plasma of patients with Alzheimer’s disease. J Neural Transm (Vienna). 2009;116:913-920. [PMID: 19415450 DOI: 10.1007/s00702-009-0224-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
132 Kimberly WT, Gilson A, Rost NS, Rosand J, Viswanathan A, Smith EE, Greenberg SM. Silent ischemic infarcts are associated with hemorrhage burden in cerebral amyloid angiopathy. Neurology 2009;72:1230-5. [PMID: 19349602 DOI: 10.1212/01.wnl.0000345666.83318.03] [Cited by in Crossref: 172] [Cited by in F6Publishing: 179] [Article Influence: 12.3] [Reference Citation Analysis]
133 Luis CA, Abdullah L, Paris D, Quadros A, Mullan M, Mouzon B, Ait-Ghezala G, Crawford F, Mullan M. Serum beta-amyloid correlates with neuropsychological impairment. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn 2009;16:203-18. [PMID: 18923961 DOI: 10.1080/13825580802411766] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
134 Herl L, Thomas AV, Lill CM, Banks M, Deng A, Jones PB, Spoelgen R, Hyman BT, Berezovska O. Mutations in amyloid precursor protein affect its interactions with presenilin/gamma-secretase. Mol Cell Neurosci 2009;41:166-74. [PMID: 19281847 DOI: 10.1016/j.mcn.2009.02.008] [Cited by in Crossref: 39] [Cited by in F6Publishing: 43] [Article Influence: 2.8] [Reference Citation Analysis]
135 Viswanathan A, Raj S, Greenberg SM, Stampfer M, Campbell S, Hyman BT, Irizarry MC. Plasma Abeta, homocysteine, and cognition: the Vitamin Intervention for Stroke Prevention (VISP) trial. Neurology 2009;72:268-72. [PMID: 19153374 DOI: 10.1212/01.wnl.0000339486.63862.db] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
136 Lönneborg A. Biomarkers for Alzheimer disease in cerebrospinal fluid, urine, and blood. Mol Diagn Ther 2008;12:307-20. [PMID: 18803429 DOI: 10.1007/BF03256296] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 1.4] [Reference Citation Analysis]
137 Bateman RJ, Klunk WE. Measuring target effect of proposed disease-modifying therapies in Alzheimer's disease. Neurotherapeutics 2008;5:381-90. [PMID: 18625449 DOI: 10.1016/j.nurt.2008.05.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.0] [Reference Citation Analysis]
138 Craig-Schapiro R, Fagan AM, Holtzman DM. Biomarkers of Alzheimer's disease. Neurobiol Dis 2009;35:128-40. [PMID: 19010417 DOI: 10.1016/j.nbd.2008.10.003] [Cited by in Crossref: 123] [Cited by in F6Publishing: 103] [Article Influence: 8.2] [Reference Citation Analysis]
139 Bates KA, Verdile G, Li Q, Ames D, Hudson P, Masters CL, Martins RN. Clearance mechanisms of Alzheimer's amyloid-β peptide: implications for therapeutic design and diagnostic tests. Mol Psychiatry 2009;14:469-86. [DOI: 10.1038/mp.2008.96] [Cited by in Crossref: 166] [Cited by in F6Publishing: 181] [Article Influence: 11.1] [Reference Citation Analysis]
140 Schupf N, Tang MX, Fukuyama H, Manly J, Andrews H, Mehta P, Ravetch J, Mayeux R. Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease. Proc Natl Acad Sci U S A. 2008;105:14052-14057. [PMID: 18779561 DOI: 10.1073/pnas.0805902105] [Cited by in Crossref: 156] [Cited by in F6Publishing: 178] [Article Influence: 10.4] [Reference Citation Analysis]
141 Reger MA, Watson GS, Green PS, Baker LD, Cholerton B, Fishel MA, Plymate SR, Cherrier MM, Schellenberg GD, Frey WH 2nd, Craft S. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J Alzheimers Dis 2008;13:323-31. [PMID: 18430999 DOI: 10.3233/jad-2008-13309] [Cited by in Crossref: 367] [Cited by in F6Publishing: 392] [Article Influence: 24.5] [Reference Citation Analysis]
142 Aluise CD, Sowell RA, Butterfield DA. Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer's disease. Biochim Biophys Acta 2008;1782:549-58. [PMID: 18760351 DOI: 10.1016/j.bbadis.2008.07.008] [Cited by in Crossref: 59] [Cited by in F6Publishing: 64] [Article Influence: 3.9] [Reference Citation Analysis]
143 Jalbert JJ, Daiello LA, Lapane KL. Dementia of the Alzheimer type. Epidemiol Rev 2008;30:15-34. [PMID: 18635578 DOI: 10.1093/epirev/mxn008] [Cited by in Crossref: 78] [Cited by in F6Publishing: 89] [Article Influence: 5.2] [Reference Citation Analysis]
144 Locascio JJ, Fukumoto H, Yap L, Bottiglieri T, Growdon JH, Hyman BT, Irizarry MC. Plasma amyloid beta-protein and C-reactive protein in relation to the rate of progression of Alzheimer disease. Arch Neurol 2008;65:776-85. [PMID: 18541797 DOI: 10.1001/archneur.65.6.776] [Cited by in Crossref: 63] [Cited by in F6Publishing: 69] [Article Influence: 4.2] [Reference Citation Analysis]
145 Oh ES, Troncoso JC, Fangmark Tucker SM. Maximizing the potential of plasma amyloid-beta as a diagnostic biomarker for Alzheimer's disease. Neuromolecular Med 2008;10:195-207. [PMID: 18543125 DOI: 10.1007/s12017-008-8035-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 29] [Article Influence: 1.5] [Reference Citation Analysis]
146 Sun X, Steffens DC, Au R, Folstein M, Summergrad P, Yee J, Rosenberg I, Mwamburi DM, Qiu WQ. Amyloid-associated depression: a prodromal depression of Alzheimer disease? Arch Gen Psychiatry 2008;65:542-50. [PMID: 18458206 DOI: 10.1001/archpsyc.65.5.542] [Cited by in Crossref: 117] [Cited by in F6Publishing: 126] [Article Influence: 7.8] [Reference Citation Analysis]
147 Szabo P, Relkin N, Weksler ME. Natural human antibodies to amyloid beta peptide. Autoimmunity Reviews 2008;7:415-20. [DOI: 10.1016/j.autrev.2008.03.007] [Cited by in Crossref: 77] [Cited by in F6Publishing: 73] [Article Influence: 5.1] [Reference Citation Analysis]
148 Modrego PJ, Monleon I, Sarasa M. The clinical significance of plasmatic amyloid A{beta}-40 peptide levels in Alzheimer's disease patients treated with galantamine. Am J Alzheimers Dis Other Demen 2008;23:286-90. [PMID: 18591211 DOI: 10.1177/1533317507313675] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
149 Hansson O, Zetterberg H, Vanmechelen E, Vanderstichele H, Andreasson U, Londos E, Wallin A, Minthon L, Blennow K. Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging. 2010;31:357-367. [PMID: 18486992 DOI: 10.1016/j.neurobiolaging.2008.03.027] [Cited by in Crossref: 168] [Cited by in F6Publishing: 186] [Article Influence: 11.2] [Reference Citation Analysis]
150 Tang BL, Kumar R. Biomarkers of Mild Cognitive Impairment and Alzheimer’s Disease. Ann Acad Med Singap 2008;37:406-410. [DOI: 10.47102/annals-acadmedsg.v37n5p406] [Reference Citation Analysis]
151 Kawarabayashi T, Shoji M. Plasma biomarkers of Alzheimer's disease. Current Opinion in Psychiatry 2008;21:260-7. [DOI: 10.1097/yco.0b013e3282fc989f] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 1.8] [Reference Citation Analysis]
152 Lopez OL, Kuller LH, Mehta PD, Becker JT, Gach HM, Sweet RA, Chang YF, Tracy R, DeKosky ST. Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study. Neurology 2008;70:1664-71. [PMID: 18401021 DOI: 10.1212/01.wnl.0000306696.82017.66] [Cited by in Crossref: 109] [Cited by in F6Publishing: 118] [Article Influence: 7.3] [Reference Citation Analysis]
153 Jellinger KA, Janetzky B, Attems J, Kienzl E. Biomarkers for early diagnosis of Alzheimer disease: 'ALZheimer ASsociated gene'--a new blood biomarker? J Cell Mol Med 2008;12:1094-117. [PMID: 18363842 DOI: 10.1111/j.1582-4934.2008.00313.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 3.0] [Reference Citation Analysis]
154 Seth A, Cui J, To E, Kwee M, Matsubara J. Complement-associated deposits in the human retina. Invest Ophthalmol Vis Sci 2008;49:743-50. [PMID: 18235023 DOI: 10.1167/iovs.07-1072] [Cited by in Crossref: 37] [Cited by in F6Publishing: 52] [Article Influence: 2.5] [Reference Citation Analysis]
155 de Jong D, Kremer BP, Olde Rikkert MG, Verbeek MM. Current state and future directions of neurochemical biomarkers for Alzheimer's disease. Clin Chem Lab Med 2007;45:1421-34. [PMID: 17970699 DOI: 10.1515/CCLM.2007.320] [Cited by in Crossref: 53] [Cited by in F6Publishing: 62] [Article Influence: 3.5] [Reference Citation Analysis]
156 Uberti D, Lanni C, Racchi M, Govoni S, Memo M. Conformationally Altered p53: A Putative Peripheral Marker for Alzheimer’s Disease. Neurodegener Dis 2008;5:209-11. [DOI: 10.1159/000113704] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
157 Xu W, Kawarabayashi T, Matsubara E, Deguchi K, Murakami T, Harigaya Y, Ikeda M, Amari M, Kuwano R, Abe K, Shoji M. Plasma antibodies to Abeta40 and Abeta42 in patients with Alzheimer's disease and normal controls. Brain Res 2008;1219:169-79. [PMID: 18534566 DOI: 10.1016/j.brainres.2008.02.060] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
158 Lichtlen P, Mohajeri MH. Antibody-based approaches in Alzheimer’s research: safety, pharmacokinetics, metabolism, and analytical tools. Journal of Neurochemistry 2008;104:859-74. [DOI: 10.1111/j.1471-4159.2007.05064.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 3.1] [Reference Citation Analysis]
159 Sager KL, Wuu J, Leurgans SE, Rees HD, Gearing M, Mufson EJ, Levey AI, Lah JJ. Neuronal LR11/sorLA expression is reduced in mild cognitive impairment. Ann Neurol 2007;62:640-7. [PMID: 17721864 DOI: 10.1002/ana.21190] [Cited by in Crossref: 73] [Cited by in F6Publishing: 83] [Article Influence: 4.9] [Reference Citation Analysis]
160 Mayeux R. Alzheimer's disease: epidemiology. Handb Clin Neurol 2008;89:195-205. [PMID: 18631744 DOI: 10.1016/S0072-9752(07)01218-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
161 Growdon JH, Irizarry MC, Scherzer C. Biomarkers for Alzheimer’s Disease and Parkinson’s Disease. Advances in Behavioral Biology. [DOI: 10.1007/978-0-387-72076-0_16] [Reference Citation Analysis]
162 Maler JM, Klafki HW, Paul S, Spitzer P, Groemer TW, Henkel AW, Esselmann H, Lewczuk P, Kornhuber J, Wiltfang J. Urea-based two-dimensional electrophoresis of beta-amyloid peptides in human plasma: evidence for novel Abeta species. Proteomics 2007;7:3815-20. [PMID: 17924594 DOI: 10.1002/pmic.200700311] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 2.6] [Reference Citation Analysis]
163 Irizarry M, Yao Y, Hyman B, Growdon J, Praticò D. Plasma F2A Isoprostane Levels in Alzheimer’s and Parkinson’s Disease. Neurodegener Dis 2007;4:403-5. [DOI: 10.1159/000107699] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 3.1] [Reference Citation Analysis]
164 Abdullah L, Paris D, Luis C, Quadros A, Parrish J, Valdes L, Keegan AP, Mathura V, Crawford F, Mullan M. The influence of diagnosis, intra- and inter-person variability on serum and plasma Abeta levels. Neurosci Lett 2007;428:53-8. [PMID: 17964720 DOI: 10.1016/j.neulet.2007.09.058] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 1.8] [Reference Citation Analysis]
165 Giedraitis V, Sundelöf J, Irizarry MC, Gårevik N, Hyman BT, Wahlund LO, Ingelsson M, Lannfelt L. The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer's disease. Neurosci Lett 2007;427:127-31. [PMID: 17936506 DOI: 10.1016/j.neulet.2007.09.023] [Cited by in Crossref: 86] [Cited by in F6Publishing: 91] [Article Influence: 5.4] [Reference Citation Analysis]
166 Qiu WQ, Summergrad P, Folstein M. Plasma Aβ42 levels and depression in the elderly. Int J Geriat Psychiatry 2007;22:930-930. [DOI: 10.1002/gps.1762] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
167 Song MS, Mook-Jung I, Lee HJ, Min JY, Park MH. Serum anti-amyloid-beta antibodies and Alzheimer's disease in elderly Korean patients. J Int Med Res 2007;35:301-6. [PMID: 17593857 DOI: 10.1177/147323000703500303] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 0.9] [Reference Citation Analysis]
168 Bibl M, Esselmann H, Mollenhauer B, Weniger G, Welge V, Liess M, Lewczuk P, Otto M, Schulz JB, Trenkwalder C, Kornhuber J, Wiltfang J. Blood-based neurochemical diagnosis of vascular dementia: a pilot study: Plasma Aβ peptides in vascular dementias. Journal of Neurochemistry 2007;103:467-74. [DOI: 10.1111/j.1471-4159.2007.04763.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 48] [Article Influence: 2.8] [Reference Citation Analysis]
169 Findeis MA. The role of amyloid beta peptide 42 in Alzheimer's disease. Pharmacol Ther 2007;116:266-86. [PMID: 17716740 DOI: 10.1016/j.pharmthera.2007.06.006] [Cited by in Crossref: 216] [Cited by in F6Publishing: 229] [Article Influence: 13.5] [Reference Citation Analysis]
170 Kauwe JS, Jacquart S, Chakraverty S, Wang J, Mayo K, Fagan AM, Holtzman DM, Morris JC, Goate AM. Extreme cerebrospinal fluid amyloid beta levels identify family with late-onset Alzheimer's disease presenilin 1 mutation. Ann Neurol 2007;61:446-53. [PMID: 17366635 DOI: 10.1002/ana.21099] [Cited by in Crossref: 58] [Cited by in F6Publishing: 67] [Article Influence: 3.6] [Reference Citation Analysis]
171 Burgos JS, Ramirez C, Sastre I, Valdivieso F. Effect of apolipoprotein E on the cerebral load of latent herpes simplex virus type 1 DNA. J Virol 2006;80:5383-7. [PMID: 16699018 DOI: 10.1128/JVI.00006-06] [Cited by in Crossref: 86] [Cited by in F6Publishing: 93] [Article Influence: 5.4] [Reference Citation Analysis]
172 Sun X, Mwamburi DM, Bungay K, Prasad J, Yee J, Lin YM, Liu TC, Summergrad P, Folstein M, Qiu WQ. Depression, antidepressants, and plasma amyloid beta (Beta) peptides in those elderly who do not have cardiovascular disease. Biol Psychiatry 2007;62:1413-7. [PMID: 17544381 DOI: 10.1016/j.biopsych.2007.01.003] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 2.0] [Reference Citation Analysis]
173 Freeman SH, Raju S, Hyman BT, Frosch MP, Irizarry MC. Plasma Abeta levels do not reflect brain Abeta levels. J Neuropathol Exp Neurol 2007;66:264-71. [PMID: 17413317 DOI: 10.1097/NEN.0b013e31803d3ae4] [Cited by in Crossref: 47] [Cited by in F6Publishing: 52] [Article Influence: 2.9] [Reference Citation Analysis]
174 Greenberg SM, Rosand J, Schneider AT, Creed Pettigrew L, Gandy SE, Rovner B, Fitzsimmons BF, Smith EE, Edip Gurol M, Schwab K, Laurin J, Garceau D. A phase 2 study of tramiprosate for cerebral amyloid angiopathy. Alzheimer Dis Assoc Disord 2006;20:269-74. [PMID: 17132972 DOI: 10.1097/01.wad.0000213845.28624.f4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
175 Qiu WQ, Sun X, Selkoe DJ, Mwamburi DM, Huang T, Bhadela R, Bergethon P, Scott TM, Summergrad P, Wang L, Rosenberg I, Folstein M. Depression is associated with low plasma Aβ42 independently of cardiovascular disease in the homebound elderly. Int J Geriat Psychiatry 2007;22:536-42. [DOI: 10.1002/gps.1710] [Cited by in Crossref: 38] [Cited by in F6Publishing: 46] [Article Influence: 2.4] [Reference Citation Analysis]
176 Ingelsson M, Hyman BT. The Molecular Basis of Alzheimer's Disease. Molecular Neurology 2007. [DOI: 10.1016/b978-012369509-3.50018-4] [Reference Citation Analysis]
177 Blasko I, Jellinger K, Kemmler G, Krampla W, Jungwirth S, Wichart I, Tragl KH, Fischer P. Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine. Neurobiol Aging. 2008;29:1-11. [PMID: 17055615 DOI: 10.1016/j.neurobiolaging.2006.09.002] [Cited by in Crossref: 75] [Cited by in F6Publishing: 78] [Article Influence: 4.4] [Reference Citation Analysis]
178 Borroni B, Di Luca M, Padovani A. Predicting Alzheimer dementia in mild cognitive impairment patients. Are biomarkers useful? Eur J Pharmacol 2006;545:73-80. [PMID: 16831417 DOI: 10.1016/j.ejphar.2006.06.023] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 1.8] [Reference Citation Analysis]
179 Spoelgen R, von Arnim CA, Thomas AV, Peltan ID, Koker M, Deng A, Irizarry MC, Andersen OM, Willnow TE, Hyman BT. Interaction of the cytosolic domains of sorLA/LR11 with the amyloid precursor protein (APP) and beta-secretase beta-site APP-cleaving enzyme. J Neurosci 2006;26:418-28. [PMID: 16407538 DOI: 10.1523/JNEUROSCI.3882-05.2006] [Cited by in Crossref: 110] [Cited by in F6Publishing: 136] [Article Influence: 6.5] [Reference Citation Analysis]
180 Mouri A, Zou L, Iwata N, Saido TC, Wang D, Wang M, Noda Y, Nabeshima T. Inhibition of neprilysin by thiorphan (i.c.v.) causes an accumulation of amyloid β and impairment of learning and memory. Behavioural Brain Research 2006;168:83-91. [DOI: 10.1016/j.bbr.2005.10.014] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 2.1] [Reference Citation Analysis]
181 Solfrizzi V, D'introno A, Colacicco AM, Capurso C, Todarello O, Pellicani V, Capurso SA, Pietrarossa G, Santamato V, Capurso A, Panza F. Circulating biomarkers of cognitive decline and dementia. Clinica Chimica Acta 2006;364:91-112. [DOI: 10.1016/j.cca.2005.06.015] [Cited by in Crossref: 74] [Cited by in F6Publishing: 83] [Article Influence: 4.4] [Reference Citation Analysis]
182 Irizarry MC. Biomarkers of Alzheimer disease in plasma. NeuroRx. 2004;1:226-234. [PMID: 15717023 DOI: 10.1602/neurorx.1.2.226] [Cited by in Crossref: 177] [Cited by in F6Publishing: 188] [Article Influence: 9.8] [Reference Citation Analysis]
183 Padovani A, Borroni B, Di Luca M. Advances on biological markers in early diagnosis of Alzheimer disease. Adv Clin Chem 2005;39:107-29. [PMID: 16013669 DOI: 10.1016/s0065-2423(04)39004-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
184 Gu SZ, Zhao XH, Quan P, Li SB, Pan BR. Alterations of serum cholinesterase in patients with gastric cancer. World J Gastroenterol 2005; 11(29): 4604-4606 [PMID: 16052698 DOI: 10.3748/wjg.v11.i29.4604] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.2] [Reference Citation Analysis]
185 Zhao XH, Gu SZ, Tian HG, Quan P, Pan BR. Clinical significance of expression of apoptotic signal proteins in gastric carcinoma tissue. World J Gastroenterol 2005; 11(25): 3846-3849 [PMID: 15991280 DOI: 10.3748/wjg.v11.i25.3846] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
186 Ravi LB, Poosala S, Ahn D, Chrest FJ, Spangler EL, Jayakumar R, Nagababu E, Mohanty JG, Talan M, Ingram DK, Rifkind JM. Red cell interactions with amyloid-β1–40 fibrils in a murine model. Neurobiology of Disease 2005;19:28-37. [DOI: 10.1016/j.nbd.2004.11.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
187 Blasko I, Kemmler G, Krampla W, Jungwirth S, Wichart I, Jellinger K, Tragl KH, Fischer P. Plasma amyloid beta protein 42 in non-demented persons aged 75 years: effects of concomitant medication and medial temporal lobe atrophy. Neurobiol Aging 2005;26:1135-43. [PMID: 15917096 DOI: 10.1016/j.neurobiolaging.2005.03.006] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 1.8] [Reference Citation Analysis]
188 Moir RD, Tseitlin KA, Soscia S, Hyman BT, Irizarry MC, Tanzi RE. Autoantibodies to redox-modified oligomeric Abeta are attenuated in the plasma of Alzheimer's disease patients. J Biol Chem 2005;280:17458-63. [PMID: 15728175 DOI: 10.1074/jbc.M414176200] [Cited by in Crossref: 68] [Cited by in F6Publishing: 72] [Article Influence: 3.8] [Reference Citation Analysis]
189 Lee PH, Bang OY, Hwang EM, Lee JS, Joo US, Mook-Jung I, Huh K. Circulating beta amyloid protein is elevated in patients with acute ischemic stroke. J Neural Transm (Vienna) 2005;112:1371-9. [PMID: 15682267 DOI: 10.1007/s00702-004-0274-0] [Cited by in Crossref: 61] [Cited by in F6Publishing: 54] [Article Influence: 3.4] [Reference Citation Analysis]
190 Hill JM, Steiner I, Matthews KE, Trahan SG, Foster TP, Ball MJ. Statins lower the risk of developing Alzheimer’s disease by limiting lipid raft endocytosis and decreasing the neuronal spread of Herpes simplex virus type 1. Medical Hypotheses 2005;64:53-8. [DOI: 10.1016/j.mehy.2003.12.058] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
191 Irizarry MC. Biomarkers of Alzheimer disease in plasma. Neurotherapeutics 2004;1:226-34. [DOI: 10.1007/bf03206606] [Reference Citation Analysis]